1. Inicio
  2. Publicaciones
  3. Outcomes and prognostic factors in intermediate-risk prostate cancer: multi-institutional analysis of the Spanish RECAP database

Outcomes and prognostic factors in intermediate-risk prostate cancer: multi-institutional analysis of the Spanish RECAP database

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Hervás A
  • Pastor J
  • González C
  • Jové J
  • Gómez A
  • Casana, M
  • Villafranca E
  • Mengual JL
  • Munoz, V
  • Henriquez I
  • Munoz, J
  • Clemente J

Abstract

PurposeTo retrospectively assess outcomes and to identify prognostic factors in patients diagnosed with intermediate-risk (IR) prostate cancer (PCa) treated with primary external beam radiotherapy (EBRT).Materials and methodsData were obtained from the multi-institutional Spanish RECAP database, a population-based prostate cancer registry in Spain. All IR patients (NCCN criteria) who underwent primary EBRT were included. The following variables were assessed: age; prostate-specific antigen (PSA); Gleason score; clinical T stage; percentage of positive biopsy cores (PPBC); androgen deprivation therapy (ADT); and radiotherapy dose. The patients were stratified into one of three risk subcategories: (1) favourable IR (FIR; GS 6,T2b or GS 3+4,T1c), (2) marginal IR (MIR; GS 3+4, T2a-b), and (3) unfavourable IR (UIR; GS 4+3 or T2c). Biochemical relapse-free survival (BRFS), disease-free survival (DFS), cancer-specific survival (CSS), and overall survival (OS) were assessed.ResultsA total of 1754 patients from the RECAP database were included and stratified by risk group: FIR, n=781 (44.5%); MIR, n=252 (14.4%); and UIR, n=721 (41.1%). Mean age was 71years (range 47-86). Mean PSA was 10.4ng/ml (range 6-20). The median radiotherapy dose was 74Gy, with mean doses of 72.5Gy (FIR), 73.4Gy (MIR), and 72.8Gy (UIR). Most patients (88%) received ADT for a median of 7.1months. By risk group (FIR, MIR, UIR), ADT rates were, respectively, 88.9, 86.5, and 86.9%. Only patients with24months of follow-up post-EBRT were included in the survival analysis (n=1294). At a median follow-up of 52months (range 24-173), respective 5- and 10-year outcomes were: OS 93.6% and 79%; BRFS 88.9% and 71.4%; DFS 96.1% and 89%; CSS 98.9% and 94.6%. Complication rates (grade 3) were: acute genitourinary (GU) 2%; late GU 1%; acute gastrointestinal (GI) 2%; late GI 1%. There was no significant association between risk group and BRFS or OS. However, patients with favourable-risk disease had significantly better 5- and 10-year DFS than patients with UIR: 98.7% vs. 92.4% and 92% vs. 85.8% (p=0.0005). CSS was significantly higher (p=0.0057) in the FIR group at 5 (99.7% vs. 97.3%) and 10 years (96.1% vs. 93.4%). On the multivariate analyses, the following were significant predictors of survival: ADT (BRFS and DFS); dose74Gy (BRFS); age (OS).ConclusionsThis is the first nationwide study in Spain to report long-term outcomes of patients with intermediate-risk PCa treated with EBRT. Survival outcomes were good, with a low incidence of both acute and late toxicity. Patients with unfavourable risk characteristics had significantly lower 5- and 10-year disease-free survival rates. ADT and radiotherapy dose74Gy were both significant predictors of treatment outcomes.

Datos de la publicación

ISSN/ISSNe:
1699-048X, 1699-3055

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico  SPRINGER-VERLAG ITALIA SRL

Tipo:
Article
Páginas:
900-909
Factor de Impacto:
0,833 SCImago ℠
Cuartil:
Q2 SCImago ℠

Citas Recibidas en Web of Science: 2

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Prostate cancer; Intermediate risk; Radiotherapy; Androgen-deprivation therapy

Campos de estudio

Proyectos asociados

MEDIDA DEL IMPACTO DE LA RADIOTERAPIA CON INTENCIÓN CURATIVA COMBINADA O NO CON TERAPIA HORMONAL SOBRE LA CALIDAD DE VIDA EN LA PRÁCTICA CLÍNICA EN EL CÁNCER DE PRÓSTATA LOCALIZADO. ESTUDIO VEPIC-ORT.

Investigador Principal: FRANCISCO JAVIER CELADA ÁLVAREZ

ONC-MA-1003 . 2016

RECAP (REGISTRO ESPAÑOL DE CÁNCER DE PRÓSTATA) TRATAMIENTO RADIOTERÁPICO EN PACIENTES CON CÁNCER DE PRÓSTATA CONFORME A LA PRÁCTICA CLÍNICA HABITUAL EN LOS SERVICIOS DE ONCOLOGÍA RADIOTERÁPICA ESPAÑOLES.

Investigador Principal: ERICA COLLADO BALLESTEROS

SEO-RAD-2017-01 . 2018

ENSAYO CLÍNICO DE FASE II DE DURVALUMAB (MEDI4736) MÁS TREMELIMUMAB CON RADIOTERAPIA CONCOMITANTE EN PACIENTES CON CARCINOMA DE VEJIGA MÚSCULO-INVASIVO LOCALIZADO, TRATADOS CON INTENCIÓN DE PRESERVACIÓN VESICAL SELECTIVA.

Investigador Principal: JOSÉ MUÑOZ LANGA

SOGUG-2017-A-IEC(VEJ)-1 . 2018

TRATAMIENTO RADIOTERÁPICO EN PACIENTES CON CÁNCER DE PRÓSTATA EN FUNCIÓN DEL NIVEL DE RIESGO CONFORME A LA PRÁCTICA CLÍNICA HABITUAL EN LOS SERVICIOS DE ONCOLOGÍA RADIOTERÁPICA ESPAÑOLES.

Investigador Principal: ERICA COLLADO BALLESTEROS

GIC-RAD-2013-01

TRATAMIENTO RADIOTERÁPICO EN PACIENTES CON CÁNCER DE PRÓSTATA CONFORME A LA PRÁCTICA CLÍNICA HABITUAL EN LOS SERVICIOS DE ONCOLOGÍA RADIOTERÁPICA ESPAÑOLES.

Investigador Principal: ERICA COLLADO BALLESTEROS

GIC-RAD-2014-01

EFECTIVIDAD DE LOS NUEVOS TRATAMIENTOS PARA EL CÁNCER DE PRÓSTATA LOCALIZADO DE BAJO RIESGO.

Investigador Principal: ALEJANDRO TORMO MICO

TTOPRÓSTATA/OBS

Cita

Compartir